A multicenter, randomized, comparative trial on the effect of febuxostat in preventing cerebral and cardiorenovascular events in patients with hyperuricemia
Latest Information Update: 10 Feb 2022
At a glance
- Drugs Febuxostat (Primary) ; Allopurinol
- Indications Cardiovascular disorders; Cerebrovascular disorders; Hyperuricaemia; Kidney disorders; Vascular disorders
- Focus Therapeutic Use
- Acronyms FREED
- 15 Feb 2022 Results of a subgroup analysis assessing the outcomes in patients with and without a history of cardiovascular disease will be published in the International Journal of Cardiology
- 04 Oct 2021 Results of post-hoc analysis assessing optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks, published in the Rheumatology.
- 07 Mar 2019 Primary endpoint of development of cerebral or cardiovascular events and all deaths has been met, according to results published in the European Heart Journal.